Quarterly ResultAug 13, 2026, 08:18 AM
Candel Therapeutics Q2 Net Loss $38.9M; Plans Aglatimagene BLA Q4 2026
AI Summary
Candel Therapeutics announced its second quarter 2026 financial results, reporting a net loss of $38.9 million and increased R&D and G&A expenses. The company plans to submit a Biologics License Application (BLA) for aglatimagene in localized prostate cancer in Q4 2026, following positive phase 3 data published in The Lancet Oncology. Candel also activated the first site for its pivotal phase 3 AURORA trial for aglatimagene in NSCLC and appointed a Chief Commercial Officer. With $201.6 million in cash and cash equivalents, the company expects to fund operations into Q1 2028.
Key Highlights
- Planning BLA submission for aglatimagene in prostate cancer in Q4 2026.
- Q2 2026 R&D expenses increased to $19.8 million from $7.0 million in Q2 2025.
- Q2 2026 G&A expenses increased to $6.9 million from $4.2 million in Q2 2025.
- Net loss for Q2 2026 was $38.9 million, compared to $4.8 million in Q2 2025.
- Cash and cash equivalents were $201.6 million as of June 30, 2026.
- Cash runway expected to fund operations into Q1 2028.
- Pivotal phase 3 clinical data for aglatimagene published in The Lancet Oncology.
- Activated first trial site for global pivotal phase 3 AURORA trial for aglatimagene in NSCLC.
Price Impact
More from CADL